2019
Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM. Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Research And Treatment 2019, 176: 303-310. PMID: 31004299, DOI: 10.1007/s10549-019-05238-4.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerLocal-regional recurrenceDisease-free survivalEffective anti-HER2 therapyLRR-free survivalAnti-HER2 therapyBreast-conserving surgeryBreast cancerRadiation therapySystemic therapyHormone receptor-positive tumorsProspective multi-institutional studyHER2-negative diseaseHER2-positive diseaseNegative axillary nodesEffective systemic therapyProspective multicenter trialEarly-stage patientsKaplan-Meier methodReceptor-positive tumorsHER2-positive tumorsMulti-institutional studyFuture investigational effortsAdjuvant trastuzumabProtocol therapyBreast Cancer Treatment
Waks AG, Winer EP. Breast Cancer Treatment. JAMA 2019, 321: 288-300. PMID: 30667505, DOI: 10.1001/jama.2018.19323.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNonmetastatic breast cancerTriple-negative tumorsBreast cancerSystemic therapyTumor subtypesMetastatic triple-negative breast cancerHormone receptor-positive tumorsBreast cancer-specific survivalHuman epidermal growth factor 2Epidermal growth factor 2Small-molecule inhibitor therapyMajor tumor subtypesCancer-specific survivalMedian overall survivalProgesterone receptor expressionMetastatic breast cancerTime of diagnosisReceptor-positive tumorsBreast cancer treatmentErbB2-positive tumorsPreoperative treatment responseERBB2 gene amplificationDistinct risk profilesPalliating symptoms
2016
Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis
Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Research And Treatment 2016, 157: 587-596. PMID: 27271765, DOI: 10.1007/s10549-016-3845-5.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerMedian overall survivalOverall survivalPopulation-based analysisDuctal carcinomaLobular carcinomaAnnual percent changeBreast cancerIncidence rateDe novo metastatic breast cancerEnd Results 9 registriesHormone receptor-positive tumorsNovo metastatic breast cancerMultivariable Cox regression modelsStage IV breast cancerAnnual age-adjusted incidence ratesAge-adjusted incidence ratesAdjusted hazard ratioBetter overall survivalDate of diagnosisReceptor-positive tumorsBreast cancer incidenceCox regression modelHazard ratioTumor histology
2015
Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors
Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. Journal Of Clinical Oncology 2015, 33: 2254-2261. PMID: 25964252, PMCID: PMC4486344, DOI: 10.1200/jco.2014.57.1349.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAsianBiomarkers, TumorBlack or African AmericanBody Mass IndexBreast NeoplasmsCause of DeathDisease-Free SurvivalEthnicityFemaleHealth Status DisparitiesHealthcare DisparitiesHispanic or LatinoHumansLogistic ModelsMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm StagingProportional Hazards ModelsRacial GroupsRisk FactorsSocioeconomic FactorsTime FactorsTreatment OutcomeTriple Negative Breast NeoplasmsUnited StatesWhite PeopleConceptsBreast cancer-specific survivalEstrogen receptor-positive tumorsCancer-specific survivalReceptor-positive tumorsBreast cancer survivalTumor characteristicsCancer survivalBreast cancerNational Comprehensive Cancer Network centersBreast cancer-specific deathHuman epidermal growth factor receptorCancer-specific deathMultivariable adjusted modelsYear of diagnosisBody mass indexProportional hazards regressionEpidermal growth factor receptorRace/ethnicityGrowth factor receptorHazards regressionMass indexRisk factorsSurvival differencesLike tumorsHigh risk
2014
Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance)
Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, Lake DE, Ma C, Blackwell KL, Winer EP, Hudis CA. Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance). Journal Of Clinical Oncology 2014, 32: 3959-3966. PMID: 25348000, PMCID: PMC4251959, DOI: 10.1200/jco.2014.56.7941.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalDouble-Blind MethodEstradiolFemaleFulvestrantHormonesHumansLapatinibMiddle AgedPostmenopauseProportional Hazards ModelsQuinazolinesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTreatment OutcomeConceptsMedian progression-free survivalProgression-free survivalOverall survivalBreast cancerHormone receptor-positive advanced breast cancerHormone receptor-positive metastatic breast cancerAdvanced ER-positive breast cancerHuman epidermal growth factor receptor 2 (HER2) statusLonger median progression-free survivalEpidermal growth factor receptor 2 statusProgesterone receptor-positive tumorsHuman epidermal growth factor receptor 2ER-positive breast cancerEpidermal growth factor receptor 2Advanced breast cancerPhase III trialsGrowth factor receptor 2Metastatic breast cancerReceptor-positive tumorsHER2-positive tumorsAromatase inhibitor treatmentFactor receptor 2Epidermal growth factor receptorDifferential treatment effectsGrowth factor receptor
2013
Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study
Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study. Clinical Breast Cancer 2013, 13: 254-263. PMID: 23829891, PMCID: PMC4084778, DOI: 10.1016/j.clbc.2013.02.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, HormonalBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm StagingPractice Patterns, Physicians'PrognosisReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRetrospective StudiesSurvival RateTamoxifenYoung AdultConceptsTrastuzumab-based therapyFirst-line trastuzumab-based therapyAdvanced HER2-positive breast cancerHER2-positive breast cancerAdjuvant trastuzumabBreast cancerClinicopathological featuresClinical benefitC-statisticHuman epidermal growth factor-2-positive breast cancerTreatment durationPredictive valueHormone receptor-positive tumorsLong-term clinical benefitPrevious adjuvant trastuzumabTreatment duration groupsRetrospective cohort studyDisease-free intervalHormone receptor positivityReceptor-positive tumorsDuration of treatmentMagnitude of benefitLow predictive valueLogistic regression modelsDifferent logistic regression modelsChoosing mastectomy over lumpectomy: Factors associated with surgical decisions in young women with breast cancer.
Rosenberg S, Sepucha K, Ruddy K, Tamimi R, Gelber S, Meyer M, Schapira L, Come S, Borges V, Winer E, Partridge A. Choosing mastectomy over lumpectomy: Factors associated with surgical decisions in young women with breast cancer. Journal Of Clinical Oncology 2013, 31: 6507-6507. DOI: 10.1200/jco.2013.31.15_suppl.6507.Peer-Reviewed Original ResearchBreast cancerYoung womenSurgical decisionStage IMulti-center cohort studyEstrogen receptor-positive tumorsReceptor-positive tumorsFinal multivariable modelFear of recurrenceDefinitive surgeryNodal involvementCohort studyMedian ageBilateral mastectomyER statusMultivariable analysisLower BMIPositive tumorsTumor sizeSurgical choiceOvarian cancerTumor gradeMultivariable modelMastectomyAge 40
2007
Heterogeneity of breast cancer and implications of adjuvant chemotherapy
Razzak AR, Lin NU, Winer EP. Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer 2007, 15: 31-34. PMID: 18224391, DOI: 10.1007/s12282-007-0007-y.Peer-Reviewed Original ResearchConceptsEstrogen receptor-positive tumorsReceptor-positive tumorsBreast cancerPositive diseasePositive tumorsAdjuvant chemotherapyDisease recurrenceClinical dataEstrogen receptor-positive cancersEstrogen receptor-negative cancersEstrogen-positive tumorsRole of chemotherapyUse of trastuzumabReceptor-positive cancersTriple-negative tumorsReceptor-negative cancersHigh nuclear gradeBreast cancer treatmentFamily of diseasesEndocrine therapyNodal statusNegative tumorsPositive cancersTumor sizeNegative cancers